What Fellow Fertility Testing Includes and Costs
Fellow offers at-home hormone and semen analysis kits that measure key fertility biomarkers such as follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, and anti-müllerian hormone for women, and sperm count, motility, and morphology for men. The company, based in San Francisco, positions its service as a first-step diagnostic option before clinical consultation. Pricing for the standard at-home test kit is around $199 as of mid-2025, with add-on panels for thyroid or ovarian reserve testing priced separately. Fellow provides results through a digital dashboard and pairs them with access to fertility specialists for follow-up guidance. The company has raised over $100 million in venture funding, with backers including a16z Bio and Khosla Ventures Forbes.
Fellow's lab is CLIA-certified and CAP-accredited, and the company states that its hormone assays use the same liquid chromatography-tandem mass spectrometry technology used in major hospital labs. Users collect samples at home using provided collection tubes and mail them back in prepaid packaging. Turnaround time for results is typically 3 to 5 business days after the lab receives the sample. Fellow's companion app allows users to track cycle data, symptom logs, and test results in one place. The company also offers a semen analysis kit for male fertility testing that evaluates concentration, motility, and morphology using computer-assisted sperm analysis FDA.
Accuracy and Clinical Validation
Fellow states that its hormone tests achieve over 98 percent sensitivity and specificity compared to central lab reference methods, though independent peer-reviewed validation studies are limited. The company has published clinical validation summaries on its website and reports alignment with Mayo Clinic Laboratories reference ranges for key hormones. For semen analysis, Fellow's computer-assisted system measures parameters in line with World Health Organization 2021 reference values for sperm concentration and motility. Users should note that at-home tests are screening tools and not a substitute for full clinical evaluation by a reproductive endocrinologist. The U.S. Food and Drug Administration has not cleared Fellow's tests as diagnostic devices, and they are labeled for informational use FDA.
Independent comparisons of at-home fertility tests, including Fellow, show that hormone results generally correlate well with serum blood draws performed in clinical labs for follicle-stimulating hormone and anti-müllerian hormone. Semen analysis at home can be affected by sample handling, temperature, and timing, which introduces more variability than lab-based testing. Fellow mitigates some of this by providing detailed collection instructions and temperature-controlled shipping. The company also offers a follow-up telehealth consultation with a licensed fertility provider to review results and discuss next steps. Users who receive abnormal results are advised to confirm findings with a clinical lab and a board-certified reproductive specialist Mayo Clinic.
Insurance Coverage and Comparison With Competitors
Fellow does not directly bill insurance for its at-home fertility test kits, and users typically pay out of pocket. However, the company provides itemized receipts with CPT and LOINC codes that customers can submit to their insurer for potential reimbursement. Some flexible spending accounts and health savings accounts cover fertility testing expenses, and Fellow's receipts include the necessary documentation for submission. In contrast, clinical fertility panels at hospitals and